Moreover, GnRH antagonists were associated with fewer CV events in patients with preexisting CV disease but not in those without preexisting CV disease in the RCT series.<h4>Conclusion</h4>GnRH antagonists appear to offer favorable safety in terms of adverse CV events and CV death compared with GnRH agonists among men diagnosed with Pca, especially those who had established CV disease at baseline.<h4>Systematic review registration</h4>https://inplasy.com/inplasy-2023-2-0009/, identifier INPLASY202320009. This evidence concerns the gene GNRH1 and posterior cortical atrophy.